Nektar Therapeutics at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 01:15AM GMT
Jess Fye JPMorgan-Analyst

Good afternoon, everyone. Welcome. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 42nd Annual Healthcare Conference today with Nektar. (Conference Instructions)

So with that, let me turn it over to Jonathan Zalevsky to present.

Jonathan Zalevsky - Nektar Therapeutics - Chief Research and Development Officer

Thank you, Jess, and hello, everyone. I'm here presenting on behalf of our CEO, Mr. Howard Robin. Unfortunately, Howard has COVID, was not able to make the conference. So I'm here to present on his behalf. And I am the R&D Chief for Nektar.

So there will be some forward-looking statements in today's presentation. And the most recent information is filed in our 10-Q from last November.

Now Nektar is a company that's focused on targeting the immune system to address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. And we have five general pillars that we focus our activities around.

The first is through

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot